The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

The U.S. Food and Drug Administration (FDA) on April 10, 2025, announced a significant policy shift aimed at reducing its reliance on animal ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The U.S. Food and Drug Administration announced it is shifting away from animal testing in the development of monoclonal ...

In other news, the US Food and Drug Administration is now reducing animal testing for drug development and will replace it ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

The FDA announced a shift away from animal testing for drug approval, citing advanced alternatives like AI and organoids ...